An interventional study of Methotrexate and salpingectomy in Ectopic Pregnancy and Infertility, sponsored by Ege University. Completed at 1 site in Turkey. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2016-03-22.
Sponsored by Ege University · Not applicable, Interventional, and Treatment
The investigators aimed to investigate the effects of salpingectomy and Methotrexate administration on ovarian reserve in ectopic pregnancy.
In this study, the effects of unilateral laparoscopic salpingectomy and single dose of systemic Methotrexate administration on ovarian reserve in patients diagnosed with ectopic pregnancy were investigated.
2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.
This study's enrollment of 131 is close to the median of 120 across 1,698 interventional studies indexed under Infertility.
Browse Infertility studies →Ege University is the lead sponsor of 365 studies on the registry; 46 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Single dose of systemic Methotrexate administered to 55 patients.
Drug: Methotrexate
Laparoscopic unilateral salpingectomy performed to 61 patients.
Procedure: salpingectomy
15 patients underwent laparoscopic unilateral salpingectomy following unsuccessful single dose of methotrexate administration.
Drug: Methotrexate · Procedure: salpingectomy
single dose systemic methotrexate administration (50 mg/m2)
Also known as: Mtx
Laparoscopic unilateral salpingectomy
Ovarian reserve assessment by measuring AMH level.
Ovarian reserve were assessed before and after treatment by measuring AMH levels.
Time frame: 1-3 months
Number of participants with treatment related adverse effect on fertility.
Rates of term delivery, spontaneous abortion, recurrent ectopic pregnancy and ongoing pregnancy for each group of patients were calculated during 2 years of follow up period.
Time frame: 2 years of follow up after treatment
Plan to share: Undecided — The investigators have not decided to share patient data yet. However, it is possible if approved by ethical committee.
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ege University